Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 11/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795230 | 0.92 | CYP4F2 (0.53) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL415499 | 0.90 | MEN1 (0.42) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL7309006 | 0.89 | USP2 (0.43) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL7443750 | 0.88 | CYP4F2 (0.45) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL1440150 | 0.88 | MEN1 (0.41) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL6186611 | 0.88 | MEN1 (0.41) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL963907 | 0.87 | USP2 (0.47) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL336548 | 0.87 | MAPK1 (0.54) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL394272 | 0.86 | MAPK1 (0.40) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL14522047 | 0.86 | MEN1 (0.39) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| EP-1070714-B1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | CYP4F2 416/4885CYP4A11 427/4885MEN1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.